Research
Hormonal
GLP-1 receptor agonists (GLP-1RAs) and dual GLP-1 and glucose-dependent insulinotropic polypeptide receptor agonists (GLP-1/GIPRA) significantly reduce body weight and adiposity.
Practitioners can expect significant weight loss and reduction in adiposity with GLP-1RA and GLP-1/GIPRA therapies.
StrongSupportsmedium confidence
these therapies have revolutionized obesity and glycemic management by inducing significant weight loss, reducing blood glucose levels, and demonstrating cardiovascular benefits in individuals with or without type 2 diabetes.
Why this rating
The claim is supported by clinical studies mentioned in the abstract.
Source
Incretin Receptor Agonism, Fat-free Mass, and Cardiorespiratory Fitness: A Narrative Review
Zhenqi Liu et al. · The Journal of Clinical Endocrinology & Metabolism · 2025
DOI 10.1210/clinem/dgaf335
reviewCited 9×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →